December 14, 2016 / 1:52 PM / 7 months ago

BRIEF-Cytomx says FDA allows it to test to its drug CX-072 in humans

1 Min Read

Dec 14 (Reuters) - Cytomx Therapeutics Inc

* Company plans to immediately initiate study and open clinical sites to support patient enrollment

* Clinical data from proclaim-072 is expected to begin to emerge in late 2017 and throughout 2018

* Press release - cytomx announces u.s. Fda clearance of investigational new drug application for phase 1/2 clinical study of anti-pd-l1 probody therapeutic, cx-072 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below